Taisho Wraps BMS Consumer Health Acquisition; iAnthus Nabs CBD For Life; Health & Wellness M&A In Brief
Executive Summary
Bristol-Myers Squibb is free to focus on drug development for patients facing serious diseases, with the divestment of its UPSA consumer health business to Taisho now complete. Separately, Harvest One Cannabis and iAnthus Capital Holdings build their capabilities to meet soaring demand for CBD and other cannabis-derived health, wellness and beauty products.
You may also be interested in...
Japan's Taisho Counts On Overseas Sales As Domestic Business Struggles During COVID-19
Strength in its overseas consumer health business, particularly in Asia, helped Taisho offset falling sales at home due to the impact of the COVID-19 pandemic in its latest nine-month reporting period.
Consumer Health Results Roundup: Genomma, Ipsen And Taisho
Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.
Wellness Industry News: MacKay Leaving CRN; Another Life-Line Recall, Ginkgo Bioworks' Second Startup, More
Duffy MacKay is leaving CRN and Andrew Shao will return for an interim period; McDaniel Life-Line recalls all lots of its Life-Line Water due to contamination; Harvest One acquires LivRelief supplement firm; and Gingko Bioworks' second startup funded $90m.